COMBIGENE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.15 SEK | -3.67% |
|
-6.25% | +17.10% |
| May. 23 | CombiGene AB Approves Election of Marcus Isaksson as Board Member | CI |
| May. 17 | CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 28.73M 2.69M | Sales 2023 | 7.01M 657K | Capitalization | 53.27M 4.99M |
|---|---|---|---|---|---|
| Net income 2022 | -6M -563K | Net income 2023 | -35M -3.28M | EV / Sales 2022 | 1.71 x |
| Net cash position 2022 | 132M 12.36M | Net cash position 2023 | 101M 9.51M | EV / Sales 2023 | -6.87 x |
| P/E ratio 2022 |
-29.4
x | P/E ratio 2023 |
-1.49
x | Employees | 8 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.67% | ||
| 1 week | -6.25% | ||
| Current month | -13.70% | ||
| 1 month | -16.22% | ||
| 3 months | -12.74% | ||
| 6 months | +24.51% | ||
| Current year | +17.10% |
1 week
3.10
3.49
1 month
3.003.95
Current year
2.664.30
1 year
2.007.86
3 years
2.0020.05
5 years
2.0033.90
10 years
2.00386.00
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Ekolind
CEO | Chief Executive Officer | 60 | 22-09-26 |
Louise Aspenberg
DFI | Director of Finance/CFO | 48 | 20-10-11 |
Daniela Morath
ADM | Chief Administrative Officer | 44 | 17-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gunilla Lundmark
BRD | Director/Board Member | 61 | 20-12-31 |
| Director/Board Member | 59 | 19-12-31 | |
| Director/Board Member | 54 | 14-09-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 3.15 | -3.67% | 13,813 |
| 24-05-23 | 3.27 | +2.83% | 6,293 |
| 24-05-22 | 3.18 | +2.58% | 10,875 |
| 24-05-21 | 3.1 | -5.49% | 22,340 |
| 24-05-20 | 3.28 | -2.38% | 29,106 |
Delayed Quote Nasdaq Stockholm, May 24, 2024 at 11:13 am EDT
More quotes
Combigene AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.
Calendar
2024-08-23
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +17.10% | 5.86M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.69% | 21.78B | |
| -10.60% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- COMBI Stock
